Subject(s)
Carcinoma, Embryonal/diagnosis , Lung Neoplasms/diagnosis , Testicular Neoplasms/diagnosis , Adult , Antineoplastic Combined Chemotherapy Protocols , Bronchoscopy , Carcinoma, Embryonal/diagnostic imaging , Carcinoma, Embryonal/secondary , Carcinoma, Embryonal/therapy , Diagnosis, Differential , Dyspnea/etiology , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Male , Neoplasm Metastasis , Orchiectomy , Testicular Neoplasms/diagnostic imaging , Testicular Neoplasms/pathology , Testicular Neoplasms/therapyABSTRACT
Beta-thalassaemia, an autosomal recessive haemoglobinopathy, ranks among the most frequent monogenetic diseases globally. The severe form of the disease, beta-thalassaemia major, is accompanied by progressive involvement of multiple organ systems as a result of the disease pathophysiology as well as iron overload from blood transfusions on a regular basis. Some of the manifestations might also be caused by medications used to manage iron overload. The purpose of this review is to highlight the rheumatological complications of beta-thalassaemia, which include musculoskeletal manifestations, such as arthritis and arthropathies, joint effusions, osteoporosis, bone fractures and myalgias, in addition to CTDs, such as pseudoxanthoma elasticum. Rheumatologists are strongly encouraged to take part in a multidisciplinary approach to the management of this debilitating disease.
Subject(s)
Blood Transfusion , Iron Overload/drug therapy , beta-Thalassemia/therapy , Arthritis/etiology , Connective Tissue Diseases/etiology , Deferiprone , Femur Head Necrosis/etiology , Fractures, Bone/etiology , Humans , Iron Chelating Agents/adverse effects , Iron Overload/etiology , Joint Diseases/chemically induced , Myalgia/etiology , Osteoporosis/etiology , Pseudoxanthoma Elasticum/etiology , Pyridones/adverse effects , Transfusion Reaction , beta-Thalassemia/complicationsABSTRACT
Headaches have been extensively reported in Antiphospholipid syndrome (APS)/Antiphospholipid antibodies (aPL)-positive patients. The aim of this study was to highlight the prevalence of headaches among APS/aPL-positive patients and discuss its association with laboratory, clinical and imaging findings. We searched the literature through Google Scholar and PubMed for publications on the epidemiology, pathogenesis, laboratory, imaging and clinical findings, and management of headaches in APS/aPL-positive patients. The following keywords were used: Antiphospholipid, Hughes syndrome, anticardiolipin, lupus anticoagulant, anti-ß2 glycoprotein I, headache, migraine, tension, and cluster. All reports published between 1969 and 2015 were included. Migraine is the most commonly reported type of headache in APS/aPL-positive patients. Thrombotic and platelet dysfunction hypotheses have been studied to uncover the pathogenic role of aPL in the development of headaches. Several studies are reporting higher levels of aPL in primary and secondary APS migraineurs, but only few reached statistical significance. Migraine patients without clinical signs/symptoms of cerebral infarction rarely show positive imaging findings. Digital subtraction angiography shows promise in demonstrating small vascular lesions otherwise not detected on computed tomography, magnetic resonance imaging, or cerebral angiograms. Although it may be solitary and harmless in many cases, the deleterious effect of migraine on the quality of life of APS patients prompts rapid diagnosis and proper management. An anticoagulation trial is advisable in APS patients with migraine as many cases of severe, refractory migraine resolved with anticoagulation therapy. The profile of migraine headaches discussed in this study permits its candidacy for inclusion in future APS classification criteria.